Pediatric Rare Disease Voucher Program Faces Expiration
Executive Summary
Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.
You may also be interested in...
Rare Pediatric Priority Review Voucher Program Seems Headed For Short-Term Renewal
Chair of the House Energy and Commerce Committee raises questions about the priority review voucher program’s value, suggesting another limited extension may be upcoming.
Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee
Next fiscal year will be a good one to redeem a voucher, and probably to qualify for one as well.
Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations
It sparked at least one analyst to question how Sarepta came up with a price for FDA's first approved Duchenne muscular dystrophy treatment.